United States:
Despite Granting A Request For Rehearing, The PTAB Maintained Its Finding That Teva's Copaxone Claims Were Unpatentable As Obvious, PTAB Litigation Blog
30 December 2016
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
In Mylan Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC
v. Yeda Research & Development Co. Ltd., IPR2015-00643; -00644; -00830, the PTAB
granted-in-part Patent Owner Teva's request for rehearing of
the Final Written Decisions finding every claim of the challenged
patents obvious over the prior art. In granting rehearing in
part, the PTAB vacated its original decisions and concurrently
entered modified Final Written Decisions maintaining that the
challenged claims are unpatentable as obvious over the prior
art.
Read the full article at
ptablitigationblog.com.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Breaking Down The EPO's Revised Practice Guidelines
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
The guidelines for examination in the European Patent Office instruct on the practice and procedure related to the examination of European patent applications...
USPTO Embraces AI Tools In New Guidance
Crowell & Moring LLP
On April 11, 2024, the USPTO published its "Guidance on Use of Artificial Intelligence-Based Tools in Practice Before the United States" in the Federal Register (the "Guidance"). As the title suggests...
USPTO Issues Guidance On Use Of AI-Based Tools
Greenberg Traurig, LLP
On April 11, 2024, the U.S. Patent and Trademark Office (USPTO) issued Guidance on Use of Artificial-Intelligence-Based Tools (Guidance), which applies existing rules and policies...